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Abstract
Introduction
Lung cancer is considered one of the most common cancers in the United States, with the second
most common type of lung cancer located in the right lung . Providing a more aggressive
approach to treatments while meeting the needs of the patients would positively impact
outcomes. Working in Radiation Oncology since 2013 as a radiation therapist and now a Medical
Dosimetrist I seek to compare the efficacy of IMRT, VMAT and hybrid IMRT/VMAT
techniques in the treatment of right lung cancer. The purpose of this study was to evaluate if the
hybrid plan would be superior to IMRT and VMAT in total coverage of right lung cancer as well
as delivering the lowest dose possible to critical structures like the heart, spinal cord, esophagus,
brachial plexus, and normal lung volume.
24

Methods
The study is a retrospective dosimetric analysis of ten randomly selected patients from a
midwestern hospital who have been previously treated for right lung cancer. For this study each
patient had three plans created comparing IMRT, VMAT and a hybrid plan. Each plan went to a
total dose of 6,600 cGy. Planning was done using Varian Eclipse treatment planning system
version 13.7.14.
Results
The results indicated the IMRT plan was the better plan out of VMAT and the hybrid treatment
plan. IMRT as well delivered the lowest dose to critical structures. Although there was a
significance all plans were within tolerance according to the institutional guidelines followed by
the NCCN guidelines version 3.2020 for non-Small Cell Lung Cancer.
Conclusion
IMRT proved to be the better plan overall. Although, there was no absolute dosimetry superiority
when comparing to the critical structures for all three plans the plans could be chosen according
to their dosimetry characteristics and which plan is beneficial for the patient.
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Introduction
Radiation therapy (RT) plays an important role in the management of all lung cancer,
with over 50% of all lung cancer patients receiving at least one modality of radiation therapy
treatment. The American Cancer society’s estimate for lung cancer alone in 2021 for the United
1

States is about 235,760 new cases of lung cancer and unfortunately about 131,8880 deaths due to
lung cancer. Each year lung cancer kills more men and women in the United States than any
21

other malignant disease. Lung cancer makes up almost twenty-five percent of all cancer deaths.
10

The most common lung cancer is NSCLC, which accounts for approximately eighty-five percent
of all lung cancers. The most common type of lung cancer is found in the right lung.
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The standard of treatment for lung cancer is chemotherapy, surgery, radiation therapy,
immunotherapy, and palliative care if the cancer is found too late and has metastasized. Creating
a radiation treatment plan for lung cancer can be challenging due to the large doses of radiation
in excess of 60 gray (Gy) to large volumes is often associated with significant risk of normal
tissue toxicity. Radiation therapy plays a fundamental role in management of thoracic tumors
5

and in doing so encompasses all the facets of oncologic care, from cure to palliation.
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With more advanced technology we can do more for the patients by introducing new
treatment techniques. The focus of this paper is introducing a new treatment technique compared
to the traditional radiation treatment techniques. This study will explore a hybrid technique that
consists of IMRT and a VMAT plan for patients with right lung cancer from a Midwestern
hospital.
For radiotherapy, lung cancer can be treated in different ways depending on the extent of
the cancer, external beam radiation is typically used. The different treatment techniques include
2

three-dimensional conformal radiotherapy (3-D CRT), Intensity-Modulated Radiotherapy
(IMRT), Tomotherapy, Image-guided Radiation therapy (IGRT), Volumetric Arc Therapy
(VMAT), Stereotactic Radiosurgery (SRS), Stereotactic body radiotherapy (SBRT) and Proton
therapy. Radiation treatment can also be given internally from a radioactive material placed
directly inside the lung cancer tumor by an implant. With external beam 3-D, IMRT, and VMAT
are the most common treatment options; for my paper I will be focusing on the following
1

treatment techniques: IMRT and VMAT.
`

Historically, radiation therapy treatments for lung cancer were planned using conformal

3-D techniques. 3-D CRT has proven effective at delivering higher doses to the target by
improved shaping of the radiation portals and conformal avoidance of normal structures when
compared to conventional radiation therapy. Compared to 3D, IMRT further improves the dose
10

conformity and sparing of organs at risks (OAR). Most patients with lung cancer typically
receive 3D or IMRT for treatment. IMRT is the latest and more advanced treatment techniques
11

when compared to 3D. The downfall of IMRT planning is the length of the treatment time and
the increased discomfort of the patients during the treatment. IMRT delivers more monitor units
(MUs) which could increase the incidence of secondary radiation-induced cancer. IMRT can
13

result in increased integral dose where larger volume of normal tissues receives low dose of
radiation.15 VMAT provides a more conformal target coverage and better sparing OARs with
shorter treatment time and fewer MUs than IMRT in treating cancer. Typically, IMRT
14

treatments for lung cancer vary from a minimum of nine to ten fields. Depending on the
treatment volume size these fields may split fields causing the 9-10 fields to double to 18-20
fields. Whereas with VMAT most patients receive two to four arcs depending on their treatment
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volume. Prior to planning, patients will first be simulated. From simulation the Radiation
Oncologist will assess which treatment plan would be best for the patient and treatment volume.
Radiation therapy simulation for thoracic cancer is performed by using a CT scan for
delineation of the target volumes and the OARs. In general patients are set up in the supine
position with their arms above their head. First, the patient will have a customized vac-lok
8

made. A vac-lok is a customizable cushion that creates a rigid and secure support around the
patient body to withstand daily treatments for up to six to eight weeks. Typically, all patients will
have a vac-lok under their upper body to help keep them immobilized. If the patient can have
both arms up above their heads this is preferred. Patients can have a knee wedge under their
knees for comfort and stability. Patients should be positioned in a reproducible manner that is
comfortable enough to reduce intrafraction movement but reproducible enough to minimize
interfraction setup errors.

8

During the simulation, this hospital uses the CT scanner GE Lightspeed. All lung patients
have a 4-dimensional computed tomography (4D CT) planning scan. 4D CT are preferred with
lung cancer due to inherent tumor movement in the thorax. 4D helps design a more precise
treatment for moving tumors because it provides better target coverage. It also allows radiation
to be delivered within a certain interval of the breathing cycle and reduces the risk of treatmentrelated side effects. 18 All lung patients will also have an FDG- PET scan to determine staging. It
is also helpful for the delineation of the primary tumor target and detects distant metastatic
disease.8\

4

Purpose
The purpose of the study is to create a hybrid plan that is a better plan overall than the
IMRT and VMAT treatment plan. The overall plan will be defined by the total coverage of the
tumor volume and the ability to limit dose to the critical structures near the treatment site. The
focus of the study is the treatment of right lung cancer. In the hybrid plan, the total number of
IMRT fields and VMAT arcs will both be minimized. The purpose of minimizing the fields in
the hybrid plan is to still achieve the same dosimetric performance as a traditional IMRT or
VMAT treatment. Another goal of the study is to explore ways to spare critical structures near
the PTV (planning target volume) while keeping good PTV coverage. The PTV includes the
gross tumor volume (GTV) with a 0.5-1.5cm margin. This margin around the PTV helps account
for respiration in case intrafraction movement occurs.
Null Hypothesis (Ho)- IMRT, VMAT delivers a better overall plan than Hybrid
Radiotherapy (IMRT and VMAT).
Alternative Hypothesis (Ha)- IMRT, VMAT does not deliver a better plan than Hybrid
Radiotherapy (IMRT and VMAT).
Null Hypothesis (Ho)- IMRT, VMAT delivers the lowest dose to critical structures than a
hybrid radiotherapy (IMRT and VMAT) plan.
Alternative Hypothesis (Ha)- IMRT, VMAT does not deliver the lowest dose to critical
structures than a hybrid radiotherapy (IMRT and VMAT) plan.

5

Literature Review
The most common lung cancer is NSCLC, which accounts for approximately eighty-five
percent of all lung cancers. The second most common lung cancer that accounts for about ten to
fifteen percent of all lung cancers is SCLC. The most common type of lung cancer is found in
24

the right lung. The primary risk factor for lung cancer is a history of smoking. Risk may
22

increase by contributions from exposure to asbestos and other industrial irritants.
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The thorax remains a challenging anatomical site for radiation delivery due to the low
electron density of the lung, respiratory and cardiac-induced tumor motion, and the proximity of
critical structures such as the esophagus and spinal cord. The course of planning a dosimetrist
takes when planning either IMRT or VMAT typically is to use one of these techniques, and not a
mixture of IMRT and VMAT due to it being more labor intensive.
To understand how the treatment plans work we must first look at the different structures
in the human lung. The lungs are a major organ of the human body with the main purpose being
to oxygenate the air to the blood. The study focuses on the anatomy of the thorax, which contains
the heart, lungs, and other vital structures within the skeletal framework that also protects some
of the abdominal organs. 8 The lung is divided into two sides, the right and left lung. The right
lung is made up of three lobes (right upper lobe (RUL), right middle lobe (RML) and the right
lower lobe (RLL) and the left lung consists of only two lobes (left upper lobe (LUL) and left
lower lobe (LLL).20 The lung is separated by the mediastinum and this area contains crucial
critical structures including the heart trachea, esophagus, spinal cord, and many lymph nodes. 25
This study will focus on the heart, esophagus, spinal cord, brachial plexus and total lung as
critical structures.

6

The common dosage for NSCLC for Pre-op Radiation therapy is 180cGyto 200 centigray (cGy) per fraction to a total dose of 45-54 Gray (Gy). Patients who receive treatment with
concurrent chemotherapy and radiation therapy are typically given 200 cGy per fraction to 60-70
Gy. Patients in post-op radiation therapy with negative margins are typically given 180- 200
cGy per fraction to a total dose of 54-60 Gy. Dosage to gross residual disease is 60- 70 Gy. For
positive SCLC Limited stage patient’s fractionation is typically 200 cGy per fraction to a total
dose of 60-66 Gy. For extensive stage SCLC patients are delivered 200-300 cGy per fraction to a
total dose of 30 -45 Gy.

23

According to Zhang (2019) study it compared conformal radiation therapy, IMRT, ARC,
conformal IMRT and conformal ARC treatment techniques. For the present study instead of
using conformal radiation therapy the primary investigator used IMRT fields instead of 3D
fields. Zhang (2019) Planning was also done by a senior physicist as compared to a graduate
student for this current study. For the IMRT plan in Zhang (2019) was worse for the minimum
dose of the PTV, but the conformality index (CI) was better. For dose to OARS the IMRT plan
had achieved lower dose to critical structures than to the CRT. For the present study the IMRT
plan will be compared to the two (VMAT and hybrid).
Another study reviewed had a comparison of the dosimetric parameters of conformal
radiation therapy, VMAT, hybrid (VMAT/3D). This study proved both VMAT and hybrid rapid
arc (H-RA) plans have a better conformity compared with CRT. The H-RA produced the best
dose homogeneity and was significantly lower than rapid arc and CRT plans. The hybrid of Chan
(2014) only included two arc and 2 static fields. For this study the VMAT and hybrid had better
conformity when compared to the conformal 3D plan. Lung dose was lowest with the hybrid.
The spinal cord gave the lowest mean dose. This study results can be beneficial toward the
7

current study. There may have some inconsistency due to the beam arrangement for the hybrid is
different from the current study. For this study the VMAT plan created will be compared to
results from the current study. The study has double arcs for the VMAT, and the hybrid had two
arcs plus two static fields. When compared to the present study the hybrid plan consisted of 5
static IMRT fields with one half arc.
According to the Silvia (2017) study, the hybrid rapid arc plan permitted safe delivery to
60-66 Gy to large lung tumors. This treatment technique spared more total and contralateral lung
volume than the 3D plans. When comparing H-RA to rapid arc (RA) plans, H-RA had better
dose homogeneity and dose parameters in the contralateral lung, which were significantly
improved. Compared to RA plans, the target volume received between 4,000 cGy and 4,500
cGy, while the maximum spinal cord dose was also significantly lower for rapidarc plans.
Another study reviewed, using a hybrid IMRT lung sparing RapidArc using two coplanar
arcs (h-RA), three lung sparing RapidArc with four coplanar arcs (4RA), and also an additional
OAR-sparing RapidArc plan made with two full arcs. The RapidArc (RA) plan was best with the
V20 being lower than h-IMRT. RA also reduced esophagus, lung, skin, heart, and had better
PTV inhomogeneity. The four-arc plan did not improve lung sparing as compared to only two
arcs, results were small differences in the lung treatment volume. But in the study using four arcs
did improve dose homogeneity in the planning target volume in which reduced high dose out of
the PTV. As for delivering the least dose to OARs the two and four arc plans resulted in similar
results. (Blom, et. al., 2015). The present study will compare IMRT, VMAT and a hybrid
combination of IMRT and VMAT treatment planning techniques for right lung cases. The
present study will have a two-arc plan for the VMAT courses and for the hybrid plan will only
use one half arc.
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According to the Verbakel (2012) study, IMRT treatment plans can improve target
coverage, but will increase the total volume dose receiving low dose irradiation. The hybridIMRT had the fastest planning technique for optimal dose distribution for PTV coverage, while
the RapidArc was also a good technique for patients whose contralateral lung V5 (CL-V5) can
be kept low. This study used a total dose of 66 Gy and compared IMRT and VMAT treatment
planning techniques for right lung cases.

Material and Methods
For this study, the samples used were selected at random. Subjects were from previously
treated patient data from a Midwest hospital from 2020 to 2021. The age of the subjects ranged
from 40 years to 84 years. All subjects were treated by the same Radiation Oncologist from the
Midwestern hospital. A total of ten patients who were de-identified were used in this study. The
population samples were chosen at random to reduce bias. Each patient had completed their
course of radiation therapy treatment. Only the treatment planning computed tomography
(TPCT) were used in this study.
Study data is from a Midwest hospital. The institution is a progressive cancer center that
treats most cancer patients in that Midwest area. Roughly less than or more than 1,200 existing
and newly diagnosed patients are treated at the institution. Alone in Radiation Oncology for
2020 roughly 765 patients were treated. Out of the 765 patients, 202 patients were lung cases
accounting for 26% of the treatment planning of 2020.
An application for institutional review board (IRB)was submitted to the Midwest
Hospital. The application outlined general information of the principal investigator, number and
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type of subjects and controls, duration of study, and abstract of the research plan. Once reviewed
by the institutional review board (IRB) the principal investigator had a presentation with the IRB
and explained the purpose of this research study. Once approved, the primary investigator had to
submit a Research Review and Approval form to be able to begin research. After samples were
selected, personal recognition was destroyed and de identified. This retrospective study presents
minimal risk to patient privacy. The study was also approved by the Grand Valley State
University (GVSU) Institutional Review Board (IRB) under the exempt review category
reference 21-191-H in Appendix.
At this midwestern clinic, the prescription used to treat lung cancer is typically to a total
dose of 6,600 cGy at 200 cGy per day for thirty fractions (fx). For the hybrid plan, the
prescription was created by using half of the prescription for the IMRT plan and VMAT plan.
The total dose was 3,300 cGy for the hybrid VMAT and 3,300 cGy for the hybrid IMRT, given
at 100 cGy per day for thirty fractions. After both hybrid plans were planned, a plan sum of both
plans was created to compare to the main IMRT and VMAT plans of a total dose of 6,600 cGy.
For contouring of the patients, the gross tumor volume (GTV) was subtracted from the
total lung volume. The critical structures such as the esophagus, heart, and spinal cord were
contoured and subtracted from the GTV. The brachial plexus was delineated by the radiation
oncologist and all avoidance structures were used on OARs to help spare dose to those
structures. For the spinal cord, an avoidance structure was created by an expansion of 0.5
centimeters to the original spinal cord, which will be used to help achieve a total dose of less
than 45 Gy. All OARs near the treatment volume had an avoidance made and cropped from the
target by 0.3 millimeter. The planning target volume and gross tumor volume were delineated by
the radiation oncologist.
10

Treatment Techniques
For this study, the IMRT plan had a total of seven to eight static IMRT fields used. The
VMAT consisted of 2 partial arcs. Arcs start and stop points depended on the location of the
tumor. The hybrid plan consisted of one-half arc and five IMRT fields. Each patient had a total
of three plans made and compared. The angle of the treatment fields depended on the location of
the tumor. Each gantry angle per field was separated by thirty to forty degrees. All the plans had
a 0-degree collimator rotation and the couch angle that was used for all plans was a 0-degrees
rotation. The VMAT plans had two half arcs which both had collimator rotations of 10 degrees
and 350 degrees. For the VMAT plan, the couch angle was at 0 degrees for both arcs. Finally, for
the hybrid plan which consisted of IMRT and VMAT, the IMRT had 5 fields and the VMAT had
one half arc with a collimator rotation of 350 degrees.
Optimization
For the PTV target, an upper was implemented using 105% of prescription, or 6,930 cGy.
Six lowers were also placed on the PTV target for optimization purposes with values of 6,600,
6,500, 6,400, 6,300, and 6,200. The final lower for 98% of the prescribed dose was valued at
6,468 cGy. Priority was set at 100% and was increased as needed depending on the overall PTV
target coverage after the plan was optimized. For each OAR, three uppers were used as a base
with 50% priority and a mean value with a 50% priority. If the OARs were not meeting
constraints, then the priorities were able to be increased to help achieve the lowest dose
achievable and to also meet the clinical requirements. Rings were used to help with dose
coverage and dose drop off. The PTV rings were extracted and had an added outer wall margin
and an inner wall margin. Each ring had a starting priority of 50%, which could be increased
11

depending on the total coverage of the target volume. For the first ring, an outer wall margin of
0.5 cm and an inner wall margin of 0 cm was used. Optimizing the first ring had an upper of
ninety five percent of the total dose (6,270 cGy). The second ring used had an outer wall margin
of 1 cm and an inner wall margin of negative 0.5 cm, which was optimized with an upper using
ninety percent of the total dose (5,940 cGy). The third ring used an outer wall margin of 1.5 cm
and an inner wall margin of negative 1 cm, which was optimized with an upper using eighty
percent of the total dose (5,280 cGy). For the fourth ring, an outer wall margin of 2 cm and an
inner wall margin of negative 1.5 cm, which was optimized with an upper with seventy percent
of the total dose (4,620 cGy). For the fifth ring, an outer wall margin of 2 cm and an inner wall
margin of negative 2 which was optimized with an upper using fifty percent of the total dose
(3,330 cGy).
For the PTV 100% of the prescription (6600cGy) had to have 95% coverage of the target
volume. The organs at risk compared included the total lung volume, esophagus, heart, spinal
cord and brachial plexus. For the total lung volume, the GTV was removed from the total lung
volume for analysis. For the total lung no more than 65% volume could receive a total dose of
5Gy. Next comparison for total lung volume was no more should receive 20 Gy for a maximum
of 30% volume. The max dose the spinal cord could receive is 45 Gy. The esophagus volume of
17% could receive 60 Gy. The mean for the entire esophagus it could receive was less than 30
Gy. The brachial plexus max dose is less than 40 Gy. The heart mean dose should be 20 Gy. For
the total heart 33% should receive 40Gy. These constraints were used for each treatment plan in
this study. Data from OARs and PTV coverage was gathered from each treatment plan from the
dose volume histograms (DVH) and plan parameters were transferred to an Excel spreadsheet.
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For this study, the plans were calculated using version 13.7.14 of the Varian Eclipse
treatment planning system. The dose calculated was with the Anisotropic Analytic Algorithm
(AAA) version 11.0.31 using 2.5mm grid resolution.
Analysis of Data
One-way repeated measures (RM) of ANOVA was used to compare correlations with
IMRT, VMAT and Hybrid Radiotherapy (IMRT and VMAT). RM ANOVA is used to determine
whether three or more group means are different where the participants are the same in each
group. 26 If Mauchly’s test statistic is significant (p-values less than 0.05) there are significant
differences between the variance of differences and sphericity is not met. If Mauchly’s test
statistic is not significant (p-value > .05) we can assume differences in variance are not
significantly different. To correct for violations of sphericity we compare to a value of 0.75 value
of the Greenhouse-Geisser. Greenhouse-Geisser (G-G) is used if the value is <.75 and HuynhFeld(H-F) is used if the value >.75. For One-way repeated measures (RM) analysis of variance
(ANOVA), a significance level of p-value less than < 0.5 is significant if greater than > 0.5 there
is no significance. If the one-way RM ANOVA is significant, we look at pairwise comparison at
the mean values comparing the plans. The sign of mean difference tells which direction the
difference is in. Pairwise comparisons are a one sample t-test of the paired differences.
Bonferroni correction was used in the post hoc to correct for multiple comparisons.

Results
The goal of this study is to determine if the hybrid plan is superior to IMRT and VMAT
and delivered the lowest dose to critical structures near the tumor for right lung cancer. This
study randomly selected ten previously treated right lung cancer patients from one midwestern
13

hospital. Grand Valley State University statistics department analyzed the data results and
concluded the one-way repeated measure ANOVA test was preferred using SAS 9.4. The results
of the data were manipulated by each column of data recorded and turned into a proportion by
comparing the data to the max value of the result. Following that, the data was adjusted for the
size of the PTV because different patients had different PTV sizes. The results should be less
than one and the lower the number the better the plan as its directly proportional to the dose
delivered to the OAR’s. The proportion of each variable will equal one or closer to one. The
mean volume of the PTV was 322cm^3. All three plans were able to achieve at least 100% dose
covering 95% of the PTV. The following were the results of the study for each treatment plan
created for right lung cancer.
Effectiveness of techniques
First, the overall plan results consist of the total tumor coverage while sparing critical
structures. We looked at descriptive statistics, shown in table 3, which includes tumor coverage
and lowest dose to critical structures, IMRT (.14826), hybrid (.157370), and VMAT (0.157656)
mean results. The VMAT plan had a higher mean number. Sphericity was not met for Mauchly’s
test, p value of (0.0003) <.05, as shown in table 2. The Huynh Feldt correction was reported
since sphericity was not met (0.871381). As shown in table 1, one-way repeated measures (RM)
ANOVA was found to be significant H-F p-value= 0.0482. Because the results of the F test are
significant, the following post hoc analysis was conducted: one sample t-tests of the paired
differences. VMAT had a higher mean value of 9.39% and p-value of 0.03721 proving a
statistical significance when compared to IMRT. The IMRT plan, had a higher mean of .81%
than the hybrid with a p value of 0.055 proving a marginal significance. When comparing
VMAT to the hybrid plan, VMAT had a higher mean of 2.86% and p-value one proving no
14

statistical significance between the two plans. For the overall plan IMRT delivered the best plan
when compared to VMAT. As well when comparing to the hybrid plan IMRT overall had the
better plan. There were no significant differences with the hybrid nor VMAT overall plan. This
can be referenced in Figure A below.
Comparison of dose to critical structures from treatment plans
Concerning 65% or less of the total lung volume receiving 500 cGy descriptive statistics
as shown in table 3, the VMAT plan (0.317025) had a higher mean number. IMRT (.294192) and
hybrid (.295781) had a lower mean number. Mauchly’s test indicated violation of sphericity, pvalue 0.0048 as shown in table 2. The Greenhouse-Geisser (0.575794) correction was reported
since sphericity was not met. As shown in table 1, one way RM ANOVA was proved to show a
difference within the three plans. One-way RM significant p-value for G-G= 0.0234, since this
was significant, we compared the pairwise comparison. Because the results of the F test are
significant, the following post hoc analysis was conducted: one sample t-tests of the paired
differences. The mean value of VMAT was 0.022833 higher than the mean of IMRT with a pvalue of 0.040239. The mean value of hybrid is also higher than that of IMRT with a mean
difference of 0.0015889 and p-value of one. The mean of VMAT was 0.021244 higher than that
of the hybrid plan and p-value of 0.11937. For comparing all three plans there was a statistically
significant difference in between the VMAT and IMRT plan with the VMAT delivering more
dose to 65% of the total lung volume receiving 500cGy or less. When comparing the hybrid plan
to both IMRT and VMAT plans there was no statistical significance.
For 30% or less of the total lung volume receiving 2000 cGy descriptive statistics was
used to compare means. As shown in the table 3, IMRT (.269731), hybrid (.275953) and the
VMAT (0.270508). The VMAT plan had a higher mean number. Mauchly’s test sphericity was
15

met, p- value of 0.6542, which can be referenced in table 2. As shown in table 1, one-way RM
ANOVA was found not significant F-value 0.82 and p-value=0.4559. For the total lung
V20<30% there was no significance between plans.
For the spinal cord max dose 4,500 cGy or less the present study looked at descriptive
statistics. As shown in the table 3, IMRT (.301304), VMAT (0.291506), hybrid had a higher
mean value (.339023). Referenced in table 2, Mauchly’s test p- value=0.1285 sphericity was met.
As shown in table 1, one-way RM ANOVA was found not significant p-value= 0.0911. There
was no statistical significance for the spinal cord receiving 4,500cGy between all three plans.
Concerning 17% or less of the esophagus receiving 6,000 cGy the descriptive statistics.
As shown in the table 3, IMRT (0.065756), hybrid (0.081626) and VMAT (0.103750) had a
higher mean value. Sphericity was not met with Mauchly’s test p- value=0.0107 referenced in
table 2, Greenhouse Geisser was reported since sphericity was not met (0.59567). As shown in
table 1, one-way RM ANOVA G-G correction 0.0817 there is marginal difference between
plans. Because the results of the F test are significant, the following post hoc analysis was
conducted: one sample t-tests of the paired differences. The mean of VMAT was 0.0221 higher
than that of the hybrid plan and a p-value of 0. 3395.VMAT had a larger mean proportion of
3.7994% and p-value of 0.23668, proving marginal statistical significance between the VMAT
and IMRT plans. Next when comparing the hybrid plan to IMRT, the hybrid plan had a larger
mean proportion of 1.5870% and a p-value of 0.3678, proving no statistical significance between
the hybrid plan and the IMRT plan. Finally, when comparing the VMAT to the hybrid plan, the
VMAT had a larger mean proportion of 2.2124% and p-value of 0.33995, proving no statistical
significance. Overall, between all three plans IMRT delivered the lowest proportion of dose to
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the esophagus and the VMAT delivered the largest dose for 17% of the esophagus receiving less
than 6,000cGy or less.
For esophagus mean dose receiving 3,400 cGy or less the descriptive statistics as shown
in the table 3, VMAT plan (0.180030) had a higher mean number, Hybrid mean (0.162164) and
the IMRT had the lowest mean of (0.150064). Mauchly’s test as referenced in table 2, indicated
no violation of sphericity, p-value 0.3649. As shown in table 1, one way RM ANOVA was found
to be significant with a p-value= 0.0014. Because the results of the F test are significant, the
following post hoc analysis was conducted: one sample t-tests of the paired differences for the
esophagus. VMAT had a larger mean proportion of 2.9966% with a significant p-value of
0.01882. When comparing the IMRT to hybrid plan the hybrid had a larger proportion of
1.2099% and a p-value of 0.11559 proving a marginally significance with alpha = 0.1 with a pvalue of 0.11559. Finally, for comparing the hybrid plan to VMAT the VMAT had a larger mean
value of 1.7866% and p-value of 0.1151, proving a marginal statistical significance between
hybrid and the VMAT plan. Overall, IMRT delivered the lowest proportion of dose to the
esophagus followed by the hybrid and the VMAT plan.
Regarding the brachial plexus descriptive statistics as shown in table 3, IMRT had the
lowest mean (0.069979), VMAT (0.074216) and hybrid (0.081626) and had a higher mean value.
Sphericity was not met with Mauchly’s test p- value=0.0003, referenced in table 2. The
Greenhouse Geisser (0.534409) correction was reported since sphericity was not met. As shown
in table 1, one-way RM ANOVA was not significant with G-G p-value= 0.4860. Altogether
there was no significance with all three plans regarding the brachial plexus.
For the mean of the heart to receive 2,000 cGy descriptive statistics is looked at
referenced in table 3. VMAT mean was the least (0.121093), IMRT mean (0.126742), and
17

VMAT (0.129358). As shown in table 2, sphericity was not met with Mauchly’s test pvalue=0.0032. The Greenhouse Geisser (0.567727) correction was reported since sphericity was
not met. As shown in table 1, one-way RM ANOVA was found not significant with G-G pvalue= 0.5400. The heart mean was evaluated for all three plans and proved no statistically
significance.
Descriptive statistics for 33% or less of the total heart volume receiving 4000 cGy, as
shown in the table 3, VMAT mean was the lowest (0.047752), hybrid (0.045985), and IMRT had
the highest mean of (0.05183). Sphericity was met with Mauchly’s test p- value=0.9848
referenced in table 2. As shown in table 1, one-way RM ANOVA was found not significant with
a p-value=0.3487. Overall, for 33% of the heart receiving 4,000cGy there was no statistical
significance.

Discussion
This study aims to show that the hybrid plan has a better plan overall than IMRT or
VMAT. As shown in Figure A, the results proved for the overall plan IMRT had the lowest
proportion when compared to the two other plans. When compared to VMAT, the IMRT plan is
the better option than the VMAT plan. When compared to the hybrid plan, there was a marginal
difference within the IMRT and hybrid plan. Overall IMRT being the better option than the
hybrid marginally. Finally, for comparing the hybrid to the VMAT plan there was no
significance. For Chan (2014) the hybrid with 2 static fields overall was superior in dosimetric
outcome in comparison for this current study the IMRT overall was the better option.
For the second hypothesis of the study if IMRT and VMAT delivers the least dose to
critical structures than the hybrid plan. The alternative hypothesis was correct in which IMRT,
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VMAT does not deliver the lowest dose to critical structures than the hybrid radiotherapy (IMRT
and VMAT) plan. All results of lowest dose to critical structures were all within NCCN
guidelines version 3.2020 Non-Small Cell Lung Cancer. Although there was a mean difference
for some of the critical structures, it was not statistically significant. The total lung volume
measured two variables. First for the V20 <30% to help prevent symptomatic pneumonitis there
was a statistical difference between VMAT and IMRT plans. Although there was a statistical
difference between the VMAT and IMRT plan, both plans were within tolerance for a treatable
plan. As compared to (Zhang 2019) the IMRT plan was higher than the VMAT plan for lowest
dose to 20Gy to 30% total lung volume.
For comparing all three plans there was a statistical significant difference in between the
VMAT and IMRT plan with the VMAT delivering more dose to 65% of the total lung volume
receiving 500cGy or less. For the V5<65% to prevent symptomatic radiation pneumonitis, it is
recommended that the V5 be limited to <65%.29 This study had comparable results as Zhang
(2019) for the V5 < 65%. Which as well had concluded their IMRT plan was superior to the
VMAT.
The most commonly practiced dose limit for the spinal cord is 45Gy in 22 to 25
fractions.30 For this study the IMRT plan marginally delivered more dose to the spinal cord than
the VMAT. This could be a discrepancy of the planner. Overall, for the spinal cord the dose
delivered between the three different plans was within tolerance. As for Zhang (2019) when
compared to IMRT to VMAT as well had no statistical significance.
The esophagus volume of 17% could receive less than 60 Gy to help prevent esophagitis.
There was a marginal difference when comparing the VMAT to the hybrid plan. Although there
was a marginal statistical significance for this OAR in the VMAT plan all three plans were
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within the tolerance limit. The mean for the entire esophagus can receive is less than 30 Gy. For
the VMAT plan it had a larger proportion compared to the IMRT and hybrid plan. For the hybrid
compared to the IMRT plan the hybrid delivered more dose to the mean of the esophagus than
the IMRT plan. Although IMRT delivered less dose the plans were within tolerance to treat.
For the brachial plexus max dose is less than 40 Gy. All three plans were within limit.
Only three out of the ten patients had the brachial plexus as an OAR since the brachial plexus
was not a factor in the other treatment volumes for right lung cancer. For the heart mean dose to
be less than 20 Gy and for 33% of the heart to receive less than 40Gy both plans were within
tolerance and proved no significance.
Limitations and future research
Some limitations of this study are worth noting. The first being the limited population
used in this study. The study used a limited patient selection for right upper lung cancer at the
same midwestern hospital. Using only 10 patients from one midwestern hospital limits the
population size as well as the potential for various cases of different patients with right upper
lung cancer. The tools associated with the version 13.7.14 Varian Eclipse treatment planning
system can be seen as a limiting factor. This system is an older system and is not as advanced as
some of the newer systems. The newer software has tools that help for optimization, which could
possibly lead to better planning results. Also, another limitation is the hybrid plan did not include
a base plan when optimizing the second plan. This could have altered the results if using the
hybrid IMRT as a base plan for the hybrid VMAT plan. An important limitation for this study is
the results are based on the discretion and experience of the planner. When comparing a senior
dosimetrist to a new graduate, the senior dosimetrist has more experience and could potentially
achieve different results. Only having one dosimetrist plan for all the treatments narrows the
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experience and external perspectives which also leads to possible errors when contouring critical
structures. To expand on the small sample size of this study, further research can be done across
regions of hospitals using different systems to maximize the data used to reinforce the study
results.

Conclusion
According to the above analysis, the overall plan demonstrated the IMRT plan had the
lowest proportion when compared to the VMAT and the hybrid treatment plans. For the critical
structures there were some differences in all thirty of the plans created but the plans were within
guidelines for a treatable plan. In the hospital, the plans can be chosen depending on patient
needs. As for using this hybrid technique for treatment it could be an option as the results proved
all three plans were treatable plans and dose to critical structures all plans were within tolerance.
The hybrid can be a good option for patients who are unable to lay for long treatment times. The
downside of the hybrid plan is the amount of work it is to plan a hybrid IMRT or hybrid VMAT.
This is not ideal if the patient is pressing for time to start their treatment. Also, it is a lot of work
for the dosimetrist to create the two hybrid plans and optimizing the two plans and meeting the
constraints. But the hybrid can be an alternative to IMRT for large treatment target that have split
fields, which can make the treatment time twice as long for a seven to eight static IMRT plan.
Further research is needed to study if the hybrid technique can be implemented into the
hospital to help reduce longer treatment times for the large lung volumes given to the
dosimetrist. The primary investigator only had the ability to use the previous patient's CT scan
and did not create nor modify the data. A future scope of work is recommended with a larger
sample size and using more than one hospital database. Having a senior dosimetrist plan the
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different treatment techniques and a recent graduate to test their planning abilities can be
beneficial to see if the same results are achieved.
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Appendix
IRB approval for Comparison of Hybrid, IMRT and VMAT techniques for Treating Right Lung
Cancer- A Scientific Review
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Figure A. Bar Chart of Overall Treatment Plan Results

Table 1. ANOVA Table
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Table 2. Mauchly’s Table

Table 3. Means Table
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